Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

May 24, 2015 12:33 AM ET


Company Overview of Boston Therapeutics, Inc.

Company Overview

Boston Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of carbohydrate-based therapeutic drugs and dietary supplements to address blood sugar management and inflammatory diseases. It produces and sells SUGARDOWN, a non-systemic complex carbohydrate-based dietary food supplement designed to support healthy post-meal blood glucose levels. The company’s lead product candidates include BTI-320, a non-systemic, carbohydrate based compound, which has completed a Phase IIb clinical trial to reduce post-meal elevation of blood glucose levels in Type 2 diabetic patients; and IPOXYN, an injectable anti-necrosis drug candidate ...

1750 Elm Street

Suite 103

Manchester, NH 03104

United States

Founded in 2009

7 Employees





Key Executives for Boston Therapeutics, Inc.

Founder, Chairman, Chief Executive Officer and Treasurer
Age: 60
Total Annual Compensation: $100.0K
Chief Financial Officer, Principal Accounting Officer and Vice President of Strategic Planning & Investor Relations
Age: 71
Total Annual Compensation: $98.4K
Compensation as of Fiscal Year 2014.

Boston Therapeutics, Inc. Key Developments

Boston Therapeutics, Inc. Reports Unaudited Earnings Results for the First Quarter Ended March 31, 2015

Boston Therapeutics, Inc. reported unaudited earnings results for the first quarter ended March 31, 2015. For the quarter, the company reported revenue of $51,329 compared with $43,827 for the same period last year. Operating loss was $734,873 compared with $1,558,130 for the same period last year. Net loss was $676,287 or $0.02 basic and diluted compared with $1,566,423 or $0.04 basic and diluted for the same period last year. Revenue increase is primarily related to revenue generated through its marketing partnership with Benchworks SD, LLC.

Boston Therapeutics, Inc. announced delayed 10-Q filing

On 05/15/2015, Boston Therapeutics, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.

Boston Therapeutics, Inc. Presents at 2nd Annual Growth Capital Expo, Apr-13-2015

Boston Therapeutics, Inc. Presents at 2nd Annual Growth Capital Expo, Apr-13-2015 . Venue: Caesars Palace, Las Vegas, Nevada, United States.

Similar Private Companies By Industry

Company Name Region
Blue Ash Therapeutics, LLC United States
Novelix Pharmaceuticals, Inc. United States
Faulk Pharmaceuticals, Inc. United States
Systemic Formulas, Inc. United States
Glycomed Incorporated United States

Recent Private Companies Transactions

Private Placement
March 18, 2015
Private Placement
March 13, 2015

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Boston Therapeutics, Inc., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at